Related Experiment Video
Updated: Aug 30, 2025
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
Clinical Translationality of KCNJ5 Mutation in Aldosterone Producing Adenoma
Takumi Kitamoto1,2, Tetsuo Nishikawa1,3
1Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Yokohama 2220036, Japan.
Abstract:
Hypertension due to primary aldosteronism poses a risk of severe cardiovascular complications compared to essential hypertension. The discovery of the KCNJ5 somatic mutation in aldosteroene producing adenoma (APA) in 2011 and the development of specific CYP11B2 antibodies in 2012 have greatly advanced our understanding of the pathophysiology of primary aldosteronism. In particular, the presence of CYP11B2-positive aldosterone-producing micronodules (APMs) in the adrenal glands of normotensive individuals and the presence of renin-independent aldosterone excess in normotensive subjects demonstrated the continuum of the pathogenesis of PA. Furthermore, among the aldosterone driver mutations which incur excessive aldosterone secretion, KCNJ5 was a major somatic mutation in APA, while CACNA1D is a leading somatic mutation in APMs and idiopathic hyperaldosteronism (IHA), suggesting a distinctive pathogenesis between APA and IHA. Although the functional detail of APMs has not been still uncovered, its impact on the pathogenesis of PA is gradually being revealed. In this review, we summarize the integrated findings regarding APA, APM or diffuse hyperplasia defined by novel CYP11B2, and aldosterone driver mutations. Following this, we discuss the clinical implications of KCNJ5 mutations to support better cardiovascular outcomes of primary aldosteronism.
Insights
Primary aldosteronism increases cardiovascular risk. Research highlights KCNJ5 mutations in adrenal adenomas and micronodules, offering insights into disease mechanisms and potential treatments for better cardiovascular outcomes.
Area of Science:
- Endocrinology and Molecular Biology
- Cardiovascular Medicine
Background:
- Primary aldosteronism (PA) presents higher cardiovascular risks than essential hypertension.
- Discoveries of KCNJ5 somatic mutations and CYP11B2 antibodies advanced PA pathophysiology understanding.
- Aldosterone-producing micronodules (APMs) and renin-independent aldosterone excess suggest a PA pathogenesis continuum.
Purpose of the Study:
- To review integrated findings on aldosterone-producing adenomas (APAs), APMs, and aldosterone driver mutations.
- To discuss the clinical implications of KCNJ5 mutations in primary aldosteronism.
- To support improved cardiovascular outcomes in PA patients.
Main Methods:
- Review of integrated findings on APA, APM, and diffuse hyperplasia defined by CYP11B2.
- Analysis of aldosterone driver mutations, including KCNJ5 and CACNA1D.
- Discussion of clinical implications of KCNJ5 mutations.
Main Results:
- KCNJ5 is a major somatic mutation in APA, while CACNA1D is prominent in APMs and idiopathic hyperaldosteronism (IHA).
- Distinct pathogenic mechanisms are suggested between APA and IHA.
- The impact of APMs on PA pathogenesis is increasingly recognized.
Conclusions:
- Understanding aldosterone driver mutations like KCNJ5 is crucial for PA.
- KCNJ5 mutations have significant clinical implications for managing PA.
- Targeting KCNJ5 mutations may improve cardiovascular outcomes in primary aldosteronism.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:24Renal Tubule and Collecting Duct
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...